Mechanism of action
Alprazolam is a triazolobenzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, the major inhibitory neurotransmitter receptor in the central nervous system. By binding to the benzodiazepine site on the GABA-A receptor complex (located at the interface between the α and γ subunits), alprazolam enhances the affinity of GABA for its receptor without directly activating the receptor itself.
This allosteric modulation increases the frequency of chloride channel opening in response to GABA, leading to hyperpolarization of the neuronal membrane and decreased neuronal excitability. The result is dose-dependent CNS depression manifesting as anxiolysis, sedation, muscle relaxation, anticonvulsant activity, and anterograde amnesia.
Alprazolam has preferential affinity for GABA-A receptors containing α1, α2, α3, and α5 subunits. The anxiolytic effects are thought to be mediated primarily through α2 and α3 subunits, while sedation and amnesia are associated with α1 subunit activity. The short half-life and high potency of alprazolam contribute to its rapid onset of action but also increase the risk of interdose rebound anxiety and withdrawal symptoms.
- Alprazolam is a high-potency, short-acting benzodiazepine that enhances GABA-A receptor activity as a positive allosteric modulator
- Black box warning: concomitant use with opioids can cause profound respiratory depression, coma, and death
- Abrupt discontinuation after chronic use can cause life-threatening withdrawal including seizures, typically 1-3 days after cessation
- Alprazolam is metabolized primarily by CYP3A4; strong inhibitors like ketoconazole are contraindicated
- Pregnancy category D: associated with increased risk of congenital malformations including oral clefts and neonatal withdrawal
- Not first-line for GAD (SSRIs preferred) and inappropriate for alcohol withdrawal (long-acting benzodiazepines preferred)
- Flumazenil can reverse benzodiazepine toxicity but may precipitate seizures in dependent patients
- Schedule IV controlled substance with high abuse and dependence potential; tolerance develops within weeks
Indications
FDA-approved indications:
- Generalized anxiety disorder (GAD): Short-term relief of anxiety symptoms
- Panic disorder: With or without agoraphobia
Off-label uses:
- Anxiety associated with depression
- Premenstrual dysphoric disorder
- Insomnia (short-term)
- Chemotherapy-induced nausea (adjunctive)
Alprazolam is intended for short-term use due to the risk of tolerance, dependence, and addiction. Clinical guidelines generally recommend limiting benzodiazepine therapy to 2-4 weeks, with the lowest effective dose used intermittently when possible. For panic disorder, longer treatment courses may be necessary, but regular reassessment and attempts at dose reduction are essential.
Benzodiazepines like alprazolam are not first-line agents for most anxiety disorders. SSRIs and SNRIs are preferred for long-term management due to superior safety profiles and lack of dependence potential. Alprazolam may be used as a bridge therapy while waiting for antidepressant onset or for acute symptom exacerbations.
Pharmacokinetics
Absorption: Alprazolam is rapidly and well absorbed from the gastrointestinal tract, with peak plasma concentrations reached within 1-2 hours of oral administration. Bioavailability is approximately 80-90%.
Distribution: The drug is highly lipophilic and readily crosses the blood-brain barrier. It is approximately 80% protein-bound, primarily to albumin. The volume of distribution ranges from 0.9 to 1.2 L/kg.
Metabolism: Alprazolam undergoes extensive hepatic metabolism via CYP3A4 (primary) and CYP3A5 oxidation to α-hydroxyalprazolam and 4-hydroxyalprazolam, both of which have minimal pharmacological activity. These metabolites are subsequently conjugated and excreted.
Elimination: The elimination half-life averages 11-16 hours (range 6-27 hours), making it a short- to intermediate-acting benzodiazepine. Metabolites are excreted primarily in urine. The half-life is prolonged in elderly patients, those with hepatic impairment, and those with obesity.
Special populations: In the elderly, mean half-life increases to approximately 16 hours. In patients with alcoholic liver disease, the half-life may be as long as 20 hours. Renal impairment has minimal effect on elimination. Asian populations may have reduced CYP3A4 activity, leading to higher plasma concentrations.
Adverse effects
Common adverse effects:
- Sedation and drowsiness (most common)
- Cognitive impairment and confusion
- Anterograde amnesia
- Impaired coordination and ataxia
- Dizziness and lightheadedness
- Headache
- Fatigue
- Dry mouth
- Constipation
- Changes in libido
Serious adverse effects:
- Dependence and withdrawal syndrome: Physical and psychological dependence can develop within weeks. Abrupt discontinuation may precipitate life-threatening withdrawal including seizures, delirium, autonomic instability, and rarely death. Withdrawal severity is greater with alprazolam than with longer-acting benzodiazepines.
- CNS depression: Profound sedation, respiratory depression (especially when combined with opioids or alcohol), coma
- Paradoxical reactions: Disinhibition, agitation, aggression, mania (more common in elderly and children)
- Falls and fractures: Particularly in elderly patients due to sedation and impaired coordination
- Cognitive impairment: Memory deficits, decreased attention, slowed processing speed; may persist with chronic use
- Overdose: Benzodiazepine overdose alone rarely causes death but is life-threatening when combined with CNS depressants
Black box warning: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. The FDA added this warning in 2016 following increasing overdose deaths.
Pregnancy and lactation: Pregnancy category D. Use during pregnancy, especially in the first trimester, has been associated with increased risk of congenital malformations including oral clefts. Neonatal withdrawal syndrome and floppy infant syndrome can occur with use near delivery. Alprazolam is excreted in breast milk and breastfeeding is generally not recommended.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to alprazolam or other benzodiazepines
- Acute narrow-angle glaucoma
- Concurrent use of strong CYP3A4 inhibitors (ketoconazole, itraconazole)
Relative contraindications and warnings:
- Respiratory disease: Chronic obstructive pulmonary disease, sleep apnea, or other conditions with compromised respiratory function; benzodiazepines can cause respiratory depression
- Hepatic impairment: Dose reduction necessary; avoid in severe liver disease
- Substance use disorders: High potential for misuse and addiction; avoid in patients with history of alcohol or drug abuse
- Elderly patients: Increased sensitivity to CNS effects, increased fall risk, cognitive impairment; included on Beers Criteria as potentially inappropriate medication
- Pregnancy: Teratogenic risk and neonatal complications
- Myasthenia gravis: May exacerbate muscle weakness
- Psychiatric comorbidity: May worsen depression; increased suicide risk, particularly when combined with alcohol
Special precautions:
Alprazolam should never be discontinued abruptly after prolonged use. Tapering should be gradual, typically reducing the dose by no more than 25% every 1-2 weeks, with slower tapers often necessary. Switching to a longer-acting benzodiazepine like diazepam before tapering may reduce withdrawal severity.
Patients should be warned about impaired ability to drive or operate machinery, and the dangers of combining alprazolam with alcohol or other CNS depressants.
Drug interactions
CYP3A4 inhibitors (increase alprazolam levels):
- Strong inhibitors: Ketoconazole, itraconazole (contraindicated), ritonavir, nelfinavir, clarithromycin
- Moderate inhibitors: Erythromycin, diltiazem, verapamil, fluconazole, grapefruit juice
- Clinical effect: Increased sedation, prolonged half-life, enhanced CNS depression
CYP3A4 inducers (decrease alprazolam levels):
- Carbamazepine, phenytoin, rifampin, St. John's wort
- Clinical effect: Reduced efficacy, potential withdrawal symptoms in dependent patients
CNS depressants (additive effects):
- Opioids: Severe respiratory depression, coma, death (black box warning)
- Alcohol: Enhanced sedation, increased overdose risk, increased disinhibition
- Other sedatives: Barbiturates, other benzodiazepines, Z-drugs (zolpidem, eszopiclone)
- Antihistamines: First-generation H1 antagonists (diphenhydramine, promethazine)
- Antipsychotics: Particularly sedating agents like quetiapine, olanzapine
Other interactions:
- Digoxin: Alprazolam may increase digoxin levels
- SSRIs/SNRIs: Fluvoxamine (strong CYP3A4 inhibitor) significantly increases alprazolam levels
- Oral contraceptives: May decrease alprazolam clearance
- Smoking: Tobacco smoking may slightly increase alprazolam clearance
The alprazolam-opioid combination is particularly dangerous and represents a major contributor to overdose deaths. This combination should be avoided whenever possible, and if unavoidable, the lowest doses and shortest duration should be used with close monitoring.
Clinical pearls
- Alprazolam has one of the highest potencies among benzodiazepines (0.5 mg alprazolam ≈ 10 mg diazepam), contributing to its abuse potential and difficulty with discontinuation.
- Interdose rebound anxiety is common due to the short half-life, leading patients to take doses more frequently than prescribed and accelerating dependence.
- Withdrawal from alprazolam is considered more severe than from longer-acting benzodiazepines like diazepam or clonazepam. Seizures can occur 1-3 days after abrupt cessation.
- Flumazenil, a benzodiazepine antagonist, can reverse alprazolam overdose but should be used with caution as it may precipitate acute withdrawal and seizures in dependent patients.
- Tolerance develops to sedative and anticonvulsant effects within days to weeks, but anxiolytic tolerance develops more slowly. This differential tolerance contributes to dose escalation.
- Alprazolam is a Schedule IV controlled substance in the United States with significant diversion and black-market availability.
- For exam purposes, know that alprazolam is inappropriate for alcohol withdrawal (diazepam or chlordiazepoxide preferred due to longer half-lives) and is not first-line for generalized anxiety disorder (SSRIs preferred).
- The extended-release formulation allows once-daily dosing and may reduce interdose anxiety, but does not eliminate dependence risk.
- Drug screening: Alprazolam may not be detected by all standard urine benzodiazepine immunoassays; specific testing may be required.
- Clinical pearl for withdrawal management: Cross-taper to diazepam using a 1:20 ratio (e.g., alprazolam 1 mg = diazepam 20 mg), then taper the diazepam slowly. The longer half-life of diazepam provides smoother withdrawal.
Practice questions
1. A 34-year-old woman with panic disorder has been taking alprazolam 1 mg three times daily for 6 months. She presents to the emergency department 48 hours after abruptly stopping the medication with anxiety, tremor, diaphoresis, and one generalized tonic-clonic seizure witnessed by EMS. Vital signs show BP 156/94 mmHg, HR 118 bpm, and RR 22/min. Which of the following is the most appropriate immediate management?
2. A 45-year-old man with generalized anxiety disorder is started on alprazolam and ketoconazole for a fungal infection. Three days later, he presents with severe drowsiness, slurred speech, and ataxia. He has been taking alprazolam 0.5 mg twice daily as prescribed. Which of the following best explains his presentation?
3. A 28-year-old woman in her first trimester of pregnancy has been taking alprazolam 0.5 mg twice daily for panic disorder for the past year. She asks about the safety of continuing the medication during pregnancy. Which of the following is the most accurate counseling regarding alprazolam use in pregnancy?
Frequently asked questions
How does alprazolam work?
Alprazolam works by enhancing the effect of GABA, the brain's main inhibitory neurotransmitter. It binds to the benzodiazepine site on GABA-A receptors and acts as a positive allosteric modulator, increasing the frequency of chloride channel opening when GABA is present. This leads to neuronal hyperpolarization and decreased excitability, producing anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. The drug does not directly activate GABA receptors but rather amplifies GABA's natural inhibitory action.
What are the side effects of alprazolam?
Common side effects include sedation, drowsiness, dizziness, impaired coordination, cognitive impairment, and anterograde amnesia. Serious risks include physical and psychological dependence (can develop within weeks), severe withdrawal syndrome with seizures upon discontinuation, respiratory depression (especially with opioids or alcohol), paradoxical agitation, and increased fall risk in elderly patients. The black box warning highlights life-threatening respiratory depression when combined with opioids. Chronic use may cause persistent cognitive deficits.
Is alprazolam a controlled substance?
Yes, alprazolam is a Schedule IV controlled substance in the United States under the Controlled Substances Act. This classification indicates it has accepted medical use but carries a potential for abuse and dependence, though lower than Schedule II or III drugs. Prescriptions for alprazolam are subject to specific regulations, and the drug is commonly diverted and misused. Due to its high potency, rapid onset, and short half-life, alprazolam has higher abuse potential than many other benzodiazepines.
Alprazolam vs lorazepam — what is the difference?
Both are high-potency benzodiazepines used for anxiety, but they differ in several ways. Alprazolam has a shorter half-life (11-16 hours) than lorazepam (10-20 hours) and is metabolized by CYP3A4, making it more susceptible to drug interactions. Lorazepam undergoes direct glucuronidation (not CYP-mediated), making it safer in liver disease and with fewer drug interactions. Lorazepam is available in intramuscular and intravenous formulations for acute use, while alprazolam is oral only. Alprazolam is considered more prone to interdose rebound anxiety and dependence due to its shorter duration and higher potency.
Can you stop alprazolam suddenly?
No, alprazolam should never be stopped suddenly after regular use, especially after more than 2-4 weeks of daily therapy. Abrupt discontinuation can cause severe withdrawal syndrome including anxiety, insomnia, tremor, sweating, seizures (most dangerous), confusion, and rarely delirium or death. Withdrawal seizures typically occur 1-3 days after cessation. Safe discontinuation requires gradual tapering, usually reducing the dose by no more than 25% every 1-2 weeks. Converting to a longer-acting benzodiazepine like diazepam before tapering may reduce withdrawal severity and make the taper smoother.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05BA12
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.